Evidence map›Paper›PMID 40045858›Full record

ArticleCurrent cancer drug targets2026

Pharmacological Evaluation of

Hailong Li, Qinghong Yu, Jiaqing Song, Haining Ding, Yian Chen, Ying Jin, Hongting Wu, Liaqat Hussain, Xiufei Gao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hailong LiSchool of Green Intelligent Pharmaceutical, Zhejiang Guangsha Vocational and Technical University of Construction, Dongyang, Zhejiang, China.
Qinghong YuFirst Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Jiaqing SongFirst Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Haining DingFirst Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yian ChenFirst Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Ying JinFirst Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Hongting WuFirst Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Liaqat HussainDepartment of Pharmacology, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan.
Xiufei GaoDepartment of Breast Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, Zhejiang, China.

Funding

National Natural Science Foundation of China 82074438, 82374447Zhejiang Provincial Department of Education Y202456494Zhejiang Provincial Traditional Chinese Medicine Scientifi Research Foundation 2024ZF121
6 · The paper itself

Abstract

introductionBreast Cancer (BC) is one of the most prevalent malignant tumors in women. The incidence of estrogen receptor-positive (ER

aimsThe objectives of the present study were to explore the impact of different APR extracts on the proliferation, migration, and invasion of ER+BC and to investigate their possible mechanism at the molecular level.

methodsVarious extracts of APR were prepared in different solvents, such as petroleum ether, ethyl acetate, n-butanol, and water. ER

resultsAPR-EA demonstrated anti-proliferative, anti-migratory, and anti-invasive effects on the ER+ T47D cell line. Thus, APR-EAE might inhibit the expression of P-PI3K/PI3K and PAkt/ Akt proteins, which subsequently represses the expression of ERα. This inhibition affects the downstream expression of the proteins CDK4 and Bcl-2, which are linked to cell growth and apoptosis.

conclusionAdditionally, APR-EA might increase the expression of P21 and Bax proteins, which are associated with cell cycle arrest and apoptosis. Overall, these effects contribute to the anti-ER+ breast cancer properties of APR-EA.

Indexed as

Antineoplastic Agents, PhytogenicBreast NeoplasmsPhosphatidylinositol 3-KinasesPlant ExtractsProto-Oncogene Proteins c-aktApoptosisCell Line, TumorCell MovementCell ProliferationCell SurvivalFemaleHumansReceptors, EstrogenRhizomeSignal TransductionAntineoplastic Agents, PhytogenicPhosphatidylinositol 3-KinasesPlant ExtractsProto-Oncogene Proteins c-aktReceptors, EstrogenAmorphophalli rhizomaBreast cancerestrogen receptor-positivePI3K/AKT pathway

Identifiers

PMID40045858
PMCPMC13284660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.